Aripiprazole-Induced Diurnal and Nocturnal Enuresis in Down's Syndrome
ARIPIPRAZOLE-INDUCED DIURNAL AND NOCTURNAL ENURESIS IN DOWN’S SYNDROME STEFANO MARINI (1) 1 Il Cireneo Foundation for Autism Spectrum Disorder, Vasto, Italy. INTRODUCTION Aripiprazole is an atypical antipsychotic with unique pharmacological profile: partial agonist for dopamine D2 and serotonin 5-HT1A and antagonist for 5-HT2A receptors. Moreover, it also exhibits affinity for dopamine D4, serotonin 5-HT2C, and 5-HT7, alpha 1 adrenergic and histamine H1 receptors [1]. Compared with other atypical antipsychotics, aripiprazole is known to have fewer adverse effects, particularly QTc prolongation, weight gain, and dysregulation of glucose and lipid metabolism, sedation, and prolactin elevation. However, common side effects are represented by headache, tremor, akathisia, nausea, vomiting, constipation, somnolence, dyspepsia, and insomnia. In the clinical practice, aripiprazole is prescribed for psychosis, bipolar disorder, adjunctive treatment of major depressive disorder, Tourette’s syndrome, irritability, and behavioral problems associated with autism spectrum disorder. Past literature highlighted clozapine, risperidone, olanzapine, and quetiapine-induced enuresis. Aripiprazole-induced enuresis has been reported as a very rare adverse effect, but contrasting data has been found in different types of patients. In children, two studies reported an aripiprazole-induced enuresis [2,3], and two studies in adults used aripiprazole to treat enuresis caused by other treatments [4,5]. CASE PRESENTATION 20-years old female drug-naive outpatient affected by Down’s syndrome and mental retardation presented auditory hallucinations, irritability, anger bursts, self-harm and aggression towards others and an increase of stereotyped behaviors. In author’s knowledge, no psychopharmacology guidelines have been published yet for the treatment of psychiatric symptoms in patients affected by Down’s Syndrome.
[Show full text]